{
    "info": {
        "nct_id": "NCT03348670",
        "official_title": "Explore the Relationship Between Single Nucleotide Polymorphisms and Abiraterone Response and Toxicity in Patients With Prostate Cancer.",
        "inclusion_criteria": "1. Clinical diagnosis of Prostate Cancer (PC)\n2. Cancer in the prostate only\n3. Prior therapy without orchiectomy\n4. Prior therapy without prostate resection\n5. Prior different chemotherapy must-need stop\n6. Have no other cancer at the same time\n7. Sign an informed consent form\n8. Receive blood-drawing\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 22 Years\nMust have maximum age of 75 Years",
        "exclusion_criteria": "1. Treatment with other anti-cancer therapies and the therapies cannot be stopped currently\n2. The patients with other serious intercurrent illness or infectious diseases\n3. Have more than one different kind of cancer at the same time\n4. Serious Allergy to Drugs\n5. Serious Bleed Tendency\n6. Serious Risks or Serious Adverse Events of the drug product label\n7. Serious Risks or Serious Adverse Events of NCI Table of Side Effects\n8. The prohibition of drug products\n9. Have no therapeutic effects\n10. Follow up to the most current label and plan for safety monitoring",
        "miscellaneous_criteria": "* Select 600 localized Prostate Cancer Patients without prostate resection\n* Dosage Duration at least 90 days\n* The usual approach group - Recruit 300 double blind random group separated prostate cancer patients currently used the Combined Chemotherapy High Dose on ZYTIGA - abiraterone acetate tablet, film coated plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated, like as the usual approach group.\n* The study approach group - Recruit 300 double blind random group separated prostate cancer patients currently used the Combined Chemotherapy Low Dose on ZYTIGA - abiraterone acetate tablet plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated, like as the study approach group."
    },
    "inclusion_lines": [
        {
            "line": "1. Clinical diagnosis of Prostate Cancer (PC)",
            "criterions": [
                {
                    "exact_snippets": "Clinical diagnosis of Prostate Cancer (PC)",
                    "criterion": "Prostate Cancer",
                    "requirements": [
                        {
                            "requirement_type": "clinical diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Cancer in the prostate only",
            "criterions": [
                {
                    "exact_snippets": "Cancer in the prostate only",
                    "criterion": "cancer location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "prostate only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Prior therapy without orchiectomy",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy without orchiectomy",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without orchiectomy",
                    "criterion": "orchiectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Prior therapy without prostate resection",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without prostate resection",
                    "criterion": "prostate resection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Prior different chemotherapy must-need stop",
            "criterions": [
                {
                    "exact_snippets": "Prior different chemotherapy must-need stop",
                    "criterion": "prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Have no other cancer at the same time",
            "criterions": [
                {
                    "exact_snippets": "no other cancer at the same time",
                    "criterion": "other concurrent cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Sign an informed consent form",
            "criterions": [
                {
                    "exact_snippets": "Sign an informed consent form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Receive blood-drawing",
            "criterions": [
                {
                    "exact_snippets": "Receive blood-drawing",
                    "criterion": "blood-drawing",
                    "requirements": [
                        {
                            "requirement_type": "ability to receive",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 22 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 22 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 22,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 75 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 75 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 75,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "8. The prohibition of drug products",
            "criterions": [
                {
                    "exact_snippets": "The prohibition of drug products",
                    "criterion": "use of drug products",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Serious Bleed Tendency",
            "criterions": [
                {
                    "exact_snippets": "Serious Bleed Tendency",
                    "criterion": "bleeding tendency",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Serious Risks or Serious Adverse Events of NCI Table of Side Effects",
            "criterions": [
                {
                    "exact_snippets": "Serious Risks or Serious Adverse Events of NCI Table of Side Effects",
                    "criterion": "serious risks or serious adverse events",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "classification",
                            "expected_value": "NCI Table of Side Effects"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Serious Risks or Serious Adverse Events of the drug product label",
            "criterions": [
                {
                    "exact_snippets": "Serious Risks ... of the drug product label",
                    "criterion": "serious risks (as per drug product label)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Serious ... Serious Adverse Events of the drug product label",
                    "criterion": "serious adverse events (as per drug product label)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. The patients with other serious intercurrent illness or infectious diseases",
            "criterions": [
                {
                    "exact_snippets": "other serious intercurrent illness",
                    "criterion": "serious intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "infectious diseases",
                    "criterion": "infectious diseases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Follow up to the most current label and plan for safety monitoring",
            "criterions": [
                {
                    "exact_snippets": "Follow up to the most current label",
                    "criterion": "follow up",
                    "requirements": [
                        {
                            "requirement_type": "adherence to label",
                            "expected_value": "most current label"
                        }
                    ]
                },
                {
                    "exact_snippets": "plan for safety monitoring",
                    "criterion": "safety monitoring",
                    "requirements": [
                        {
                            "requirement_type": "plan",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Serious Allergy to Drugs",
            "criterions": [
                {
                    "exact_snippets": "Serious Allergy to Drugs",
                    "criterion": "drug allergy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Have no therapeutic effects",
            "criterions": [
                {
                    "exact_snippets": "Have no therapeutic effects",
                    "criterion": "therapeutic effects",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Treatment with other anti-cancer therapies and the therapies cannot be stopped currently",
            "criterions": [
                {
                    "exact_snippets": "Treatment with other anti-cancer therapies",
                    "criterion": "treatment with other anti-cancer therapies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the therapies cannot be stopped currently",
                    "criterion": "ability to stop other anti-cancer therapies",
                    "requirements": [
                        {
                            "requirement_type": "ability to stop",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Have more than one different kind of cancer at the same time",
            "criterions": [
                {
                    "exact_snippets": "Have more than one different kind of cancer at the same time",
                    "criterion": "number of different kinds of cancer",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "kinds"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "* Dosage Duration at least 90 days",
            "criterions": [
                {
                    "exact_snippets": "Dosage Duration at least 90 days",
                    "criterion": "dosage duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The usual approach group - Recruit 300 double blind random group separated prostate cancer patients currently used the Combined Chemotherapy High Dose on ZYTIGA - abiraterone acetate tablet, film coated plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated, like as the usual approach group.",
            "criterions": [
                {
                    "exact_snippets": "prostate cancer patients",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "double blind random group separated",
                    "criterion": "randomization and blinding",
                    "requirements": [
                        {
                            "requirement_type": "randomized",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "double blind",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "currently used the Combined Chemotherapy High Dose on ZYTIGA - abiraterone acetate tablet, film coated plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated",
                    "criterion": "current treatment regimen",
                    "requirements": [
                        {
                            "requirement_type": "medications",
                            "expected_value": [
                                "ZYTIGA (abiraterone acetate)",
                                "RAYOS (prednisone)",
                                "ORGOVYX (relugolix)"
                            ]
                        },
                        {
                            "requirement_type": "chemotherapy dose",
                            "expected_value": "high"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The study approach group - Recruit 300 double blind random group separated prostate cancer patients currently used the Combined Chemotherapy Low Dose on ZYTIGA - abiraterone acetate tablet plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated, like as the study approach group.",
            "criterions": [
                {
                    "exact_snippets": "prostate cancer patients",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "currently used the Combined Chemotherapy Low Dose on ZYTIGA - abiraterone acetate tablet plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated",
                    "criterion": "current use of Combined Chemotherapy Low Dose regimen (ZYTIGA + RAYOS + ORGOVYX)",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "regimen components",
                            "expected_value": [
                                "ZYTIGA (abiraterone acetate tablet)",
                                "RAYOS (prednisone tablet, delayed release)",
                                "ORGOVYX (relugolix tablet, film coated)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Select 600 localized Prostate Cancer Patients without prostate resection",
            "criterions": [
                {
                    "exact_snippets": "localized Prostate Cancer Patients",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "localization",
                            "expected_value": "localized"
                        }
                    ]
                },
                {
                    "exact_snippets": "without prostate resection",
                    "criterion": "prostate resection",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}